Publications by authors named "C I Cann"
Despite decreased incidence rates in average-age onset patients in high-income economies, colorectal cancer is the third most diagnosed cancer in the world, with increasing rates in emerging economies. Furthermore, early onset colorectal cancer (age ≤50 years) is of increasing concern globally. Over the past decade, research advances have increased biological knowledge, treatment options, and overall survival rates.
View Article and Find Full Text PDFArticle Synopsis
- A study examined the consistency of genetic mutations in tumor tissue before treatment and circulating tumor DNA (ctDNA) after treatment in patients with metastatic squamous cell carcinoma of the anal canal (SCCA).
- They found that 34.5% of mutations in posttreatment ctDNA matched those from pretreatment tumor tissue, while 47.6% of pretreatment mutations were also found in posttreatment ctDNA.
- The results indicate significant changes in mutations post-treatment, suggesting ctDNA is a valuable tool for tracking tumor evolution and identifying new actionable mutations, warranting further research with larger patient groups.
Colorectal cancer results in the deaths of hundreds of thousands of patients worldwide each year, with incidence expected to rise over the next two decades. In the metastatic setting, cytotoxic therapy options remain limited, which is reflected in the meager improvement of patient survival rates. Therefore, focus has turned to the identification of the mutational composition inherent to colorectal cancers and development of therapeutic targeted agents.
View Article and Find Full Text PDFPurpose: Patients with small-cell lung cancer (SCLC) have an exceptionally poor prognosis, calling for improved real-time noninvasive biomarkers of therapeutic response.
Experimental Design: We performed targeted error-correction sequencing on 171 serial plasmas and matched white blood cell (WBC) DNA from 33 patients with metastatic SCLC who received treatment with chemotherapy (n = 16) or immunotherapy-containing (n = 17) regimens. Tumor-derived sequence alterations and plasma aneuploidy were evaluated serially and combined to assess changes in total cell-free tumor load (cfTL).